Research
DRNI Members Research is a list of ongoing and completed research carried out by DRNI members.
You can search via project type, disease, or Principal Investigator/Researcher name.
Search
Research type
Disease area
Field of research
- Basic/Discovery Research (38)
- Clinical Research (27)
- Social Research (12)
- Public Health (6)
- Connected Health (5)
- Economic Research (4)
- Brain Health (3)
- Neurodegeneration (2)
- Social research, Economic research (2)
- Ageing and Nutrition research (1)
- Clinical Research, Social Research, Connected Health, Economic Research (1)
- Nursing care (1)
- Occupational Therapy (1)
- Pharmacology & Therapeutics (1)
Increased knowledge about the pre-clinical and early clinical stages of Alzheimer's disease (AD) will be key in developing preventative strategies for the disease as well as development of therapeutic treatment strategies. In addition, this approach will contribute to the development of biomarkers for the early diagnosis of AD.
In 2013, the Irish National Audit of Dementia audited 35 acute hospitals in the Republic of Ireland, interviewing the senior hospital managers and geriatricians; directly observing the environment/ interviewing the clinical nurse manager of 77 wards, and reviewing 660 healthcare records of people with dementia who had been admitted to the hospitals.
As part of the BIOMARKPD initiative the Irish Network for Biomarkers in Neurodegeneration (IN-BIND) was established. It is a research infrastructure aimed at creating a functional network for clinical and laboratory based scientists working in this area. Similar to BIOMARKPD, the aims of IN-BIND are the standardisation of biomarker measurement across Ireland and Europe to include i) sample collection, ii) measurement, iii) and interpretation.
As part of the BIOMARKPD initiative the Irish Network for Biomarkers in Neurodegeneration (IN-BIND) was established. It is a research infrastructure aimed at creating a functional network for clinical and laboratory based scientists working in this area. Similar to BIOMARKPD, the aims of IN-BIND are the standardisation of biomarker measurement across Ireland and Europe to include i) sample collection, ii) measurement, iii) and interpretation.
No new Alzheimer's drug treatment had be licensed for 20 years until 2021, when the first Alzheimer's disease-modifying therapy (DMT) was licensed in the USA, giving hope of slowing/reversing the disease. Several new DMTs are expected. Unfortunately, offering DMTs in Ireland requires significant changes in Memory Clinic set-up, due to high drug costs and need for careful monitoring. Moreover, DMTs only work in people in early Alzheimer's, which is often unrecognized in Ireland.
Adopting a three pronged multidisciplinary research approach the programme is organised in three specific and interlinked work packages relating to Amyotrophic Lateral Scerosis, spanning clinical, epidemiological and health services research including health economics. The research aims to generate a framework for optimal management of ALS and explore its relevance for other neurological conditions.
Adopting a three pronged multidisciplinary research approach the programme is organised in three specific and interlinked work packages relating to Amyotrophic Lateral Scerosis, spanning clinical, epidemiological and health services research including health economics. The research aims to generate a framework for optimal management of ALS and explore its relevance for other neurological conditions.
Project Aim(s): This project aimed to utilize data from the Irish Register and the national ALS service to generate a framework for care for Irish ALS patients based on their clinical phenotype, rate of progression and long term prognosis. The objective was to design, estimate the costs, and measure the benefits of a multifaceted care programme that incorporates the key clinical and prognostic elements of ALS.
The Living with Dementia (LiD) supports and promote post-graduate research in dementia care. Its research programme is designed to tackle the stigma and marginalisation of people with dementia, enhance practice and service provision and ultimately improve quality of life for people with dementia.